Munich-based mk2 Biotech­nolo­gies today announced the receipt of sev­er­al mil­lion Euros in seed fund­ing to accel­er­ate the fur­ther growth of the com­pa­ny. In par­tic­u­lar, the com­pa­ny thrives to accom­plish addi­tion­al devel­op­ment mile­stones towards indus­tri­al­iz­ing its nov­el pep­tide pro­duc­tion plat­form. The financ­ing round was led by OCCIDENT, with sig­nif­i­cant funds also com­ing from prime­CROWD and Seed­Blink along­side co-financ­ing from high net worth individuals.

mk2 Biotech­nolo­gies’ objec­tive is to apply its unique plat­form approach for the syn­the­sis and purifi­ca­tion of authen­tic pep­tides at large scales which can be broad­ly applied in sev­er­al mar­ket seg­ments. Using our syn­the­sis tech­nol­o­gy, we can exceed both the qual­i­ty require­ments and the cost expec­ta­tions. The key to our process is that we were able to elim­i­nate the exist­ing bot­tle­necks of estab­lished tech­nolo­gies” said Dr. Sebas­t­ian Man­gold, Man­ag­ing Direc­tor and one of the three co-founders of mk2 Biotech­nolo­gies. “The fund­ing com­mit­ted by this expe­ri­enced syn­di­cate rep­re­sents a fur­ther val­i­da­tion of our tech­nol­o­gy and reflects the recent devel­op­ment of the bioac­tives mar­ket. The fund­ing will enable us to con­tin­u­ous­ly improve our plat­form and ramp up our pro­duc­tion in order to move our first prod­uct can­di­dates towards the appli­ca­tion in vol­ume mar­kets such as cos­met­ics, food & bev­er­ages, agri­cul­ture and phar­ma­ceu­ti­cals.”

This fall, mk2 Biotech­nolo­gies will trans­fer its R&D facil­i­ties to the Inno­va­tion and Start-Up Cen­ter for Biotech­nol­o­gy in Mar­tin­sried (IZB), just out­side of Munich, which will enable the tar­get­ed growth of team, oper­a­tions and busi­ness. “We are very much look­ing for­ward to our new facil­i­ties and the co-locat­ed com­pa­nies main­ly active in the phar­ma­ceu­ti­cals indus­try. We expect to lever­age respec­tive syn­er­gies and accel­er­ate not only our indus­tri­al­ly applic­a­ble prod­uct can­di­dates, but par­tic­u­lar­ly our pep­tide-based APIs which are already in the devel­op­ment pipeline” com­ple­ment­ed Dr. Sebas­t­ian Mangold.

Cédric Bar­ra, Senior Invest­ment Man­ag­er at OCCIDENT, com­ment­ed: “We see a lot of poten­tial in the appli­ca­tion of high-qual­i­ty pep­tides. With the tech­nol­o­gy plat­form and the know-how that the team at mk2 brings along, the com­pa­ny is in an excel­lent posi­tion for fur­ther devel­op­ment. We are very much look­ing for­ward to work­ing with this moti­vat­ed team in the future.”

Ronald Rap­berg­er, Chief Invest­ment Offi­cer of prime­CROWD, added: “Being a mol­e­c­u­lar biol­o­gist myself, I’m con­fi­dent in the abil­i­ty of this out­stand­ing team to bring the tech­nol­o­gy from the lab to the mass mar­kets. This will final­ly make pep­tides avail­able for cur­rent­ly under­served appli­ca­tion areas and at com­pet­i­tive prices.”

Pep­tides, which are short amino acid chains, can have extra­or­di­nary prop­er­ties and modes of action. This sub­stance class has been iden­ti­fied to be very promis­ing for high­ly attrac­tive appli­ca­tions in the areas of per­son­al care, food & bev­er­ages (e.g. fla­vors, nutri­tion and con­ser­va­tion), ani­mal breed­ing (e.g. antibi­otics sub­sti­tutes) and crop cul­ti­va­tion (e.g. fungi­cide and fer­til­iz­er sub­sti­tutes). How­ev­er, estab­lished pro­duc­tion meth­ods are very cost­ly and not scal­able. Due to the enor­mous­ly high prices, despite their often out­stand­ing prop­er­ties and the broad inter­est of the indus­try, pep­tides have so far not been applic­a­ble in prod­ucts on the mass mar­ket. mk2 Biotech­nolo­gies pre­cise­ly address­es this chal­lenge via a pro­pri­etary process that allows the scal­able and thus cost-effi­cient pro­duc­tion of high-puri­ty pep­tides for a wide range of appli­ca­tions. There­fore, mk2 Biotech­nolo­gies pro­vides the yet miss­ing tool for the appli­ca­tion of pep­tides in mass markets.


About mk2 Biotechnologies

mk2 Biotech­nolo­gies GmbH devel­ops, pro­duces and inves­ti­gates pep­tides at high­est puri­ty and qual­i­ty stan­dards using a rev­o­lu­tion­ary scal­able syn­the­sis tech­nol­o­gy. This way mk2 Biotech­nolo­gies enables the pro­duc­tion of authen­tic pep­tides, regard­less of their phys­i­cal or chem­i­cal prop­er­ties, at large scales and low cost. The pre-seed activ­i­ties were financed with grants by the Zei­dler-Forschungs-Stiftung and the fund­ing pro­grams “FLÜGGE” and “EXIST-Forschungstrans­fer”. Sev­er­al ear­ly-stage start-up awards includ­ing the Science4Life Ven­ture Cup and the TUM IdeAward had rec­og­nized the unique approach and its high potential.

Press Con­tact:

mk2 Biotech­nolo­gies GmbH
Dr. Kon­stan­ti­nos Antonopoulos
Fall­strasse 9
81369 Munich/Germany



OCCIDENT is an inter­na­tion­al ven­ture cap­i­tal investor with offices in Munich and Zug, is own­er-man­aged and invests own wealth. Its aim is to make a pos­i­tive con­tri­bu­tion to soci­ety through sus­tain­able and mean­ing­ful investments.

OCCIDENT invests in inno­v­a­tive deep tech start-ups with excel­lent tech­nolo­gies in the fields of life sci­ences, high-tech and dig­i­tal with broad appli­ca­tion pos­si­bil­i­ties and the poten­tial for fur­ther val­ue-gen­er­at­ing devel­op­ments. The geo­graph­ic focus is Ger­many and Switzer­land. The pre­ferred stage for ini­tial financ­ing is from seed rounds or lat­er and from 0.5 mil­lion euros. OCCIDENT dis­tin­guish­es itself in par­tic­u­lar by its in-depth knowl­edge of the tech­nol­o­gy and the ver­sa­tile sup­port offered to its port­fo­lio com­pa­nies by its com­pe­tent team of experts. For more infor­ma­tion, please vis­it


About prime­CROWD

prime­CROWD is one of the largest start­up investor net­works in the DACH region and includes more than 2,500 investors as well as numer­ous incu­ba­tors, accel­er­a­tors and VCs.

prime­CROWD acts as an inter­face between investors and star­tups with a focus on ear­ly-stage and growth financ­ing in the tech­nol­o­gy, health­care, dig­i­tal econ­o­my and sus­tain­abil­i­ty sec­tors. Its declared goal is to accom­pa­ny star­tups through­out the entire invest­ment process.

Since its foun­da­tion in 2015, invest­ments in 28 star­tups and in the amount of more than EUR 20 mil­lion have been real­ized (two exits). For more infor­ma­tion, please vis­it


About Seed­Blink

Seed­Blink is the fastest grow­ing invest­ing plat­form spe­cial­ized in sourc­ing, vet­ting, financ­ing, and scal­ing Euro­pean tech start-ups. The com­pa­ny aims to sim­pli­fy the invest­ment process for retail and accred­it­ed investors by com­bin­ing crowd reach, busi­ness angel flex­i­bil­i­ty, and Ven­ture Cap­i­tal exper­tise, all in one inter­net plat­form. SeedBlink’s boom­ing investors com­mu­ni­ty and the selec­tion of start-ups are at the core of the platform’s suc­cess, along with opti­mized port­fo­lio diver­si­fi­ca­tion through the­sis-aligned match­ing and engage­ment tools. For more infor­ma­tion, please vis­it